<DOC>
	<DOCNO>NCT02608736</DOCNO>
	<brief_summary>This study evaluate addition valproic acid chemopreventive drug head neck squamous cell carcinoma ( HNSCC ) patient sign recurrence residual disease . The participant randomize 1:1 ( valproic acid : placebo ) . The primary outcome document histone acetylation DNA methyltransferase expression ( DNMT ) saliva collect participant compare valproic acid arm placebo arm .</brief_summary>
	<brief_title>Chemoprevention Head Neck Squamous Cell Carcinoma ( HNSCC ) With Valproic Acid</brief_title>
	<detailed_description>Chemoprevention attractive strategy reduce incidence squamous cell carcinoma head neck , although past trial demonstrate feasibility . Valproic acid ( VA ) modifier epigenetic event histone deacetylase inhibitor cause DNMT degradation . The histone deacetylase inhibitor ( e.g . VA ) encompass new class anti-tumor drug , affect multiple pathway relate tumor initiation progression due histone non-histone protein acetylation DNMT degradation . VA promote histone acetylation orally administer dose 20-40 mg/kg , per day 1000/1500 mg , per day . Initially author study saliva participant document saliva histone acetylation difference DNMT expression saliva exist compare valproic acid arm placebo arm ( biological validation ) give placebo valproic acid three month . This initial step big project . If author prove difference histone acetylation and/or DNMT expression group launch randomize , double blind , placebo control clinical trial ( phase 3 clinical trial ) , evaluate VA action chemopreventive agent HNSCC patient usually carry high chance develop recurrence ( stage III/IV ) second primary malignancy ( stage I/II/III/IV ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Patients sign formal consent ; Previous history head neck squamous cell carcinoma three year followup ; History squamous cell carcinoma follow subsites : oral cavity , oropharynx , larynx hypopharynx ; Absence active malignant disease ( HNSCC ) least three month followup ( without sign residual disease , recurrence second primary invasive tumor ) ; Normal liver , hematologic renal function . Eastern Cooperative Oncology Group ( ECOG ) Performance Status : 0 , 1 2 ; Smoking history ( current smoker former smoker ) . Former user define patient quit smoke least one year prior diagnosis smoke 100 cigarette lifetime . Any active malignancy ; History invasive malignancy ( HNSCC ) diagnose within last 2 year ( control nonmelanoma skin cancer exception ) ; History hepatitis B , hepatitis C , HIV , chronic liver disease chronic pancreatic disease ; Any comorbid medical psychiatric disorder well control ; Patients immunosuppression systemic corticosteroid therapy treat active autoimmune disease ; Patients still document toxicity great grade 1 ( CTCEA NCI v4.0 ) due previously treat HNSCC ; Patients pregnant breastfeeding ; Patients routine use follow medication due drug interaction : phenytoin , carbamazepine , barbiturate , chlorpromazine , diazepam , clonazepam , lamotrigine , primidone , amitriptyline , nortriptyline , ethosuximide , warfarin , tolbutamide topiramate ; Any medical condition mental disorder potentially increase risk trial ( e.g . epilepsy , active infection , schizophrenia ) ; Patients already valproic acid use due neurological psychiatric disorder ; Patients allergic/intolerant valproic acid ; Patients alcoholism history within past year alcoholism treatment period ; Institutionalized patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>head neck squamous cell carcinoma</keyword>
	<keyword>histone deacetylases</keyword>
	<keyword>valproic acid</keyword>
	<keyword>acetylation</keyword>
	<keyword>chemoprevention</keyword>
	<keyword>DNA methyltransferase</keyword>
	<keyword>methylation</keyword>
</DOC>